Precision medicine in clinical oncology: the journey from IgG antibody to IgE

Judit Fazekas-Singer, Josef Singer, Erika Jensen-Jarolim

Research output: Journal article (peer-reviewed)Journal article

1 Citation (Scopus)


PURPOSE OF REVIEW: Cancer is one of the leading causes of death and the incidence rates are constantly rising. The heterogeneity of tumors poses a big challenge for the treatment of the disease and natural antibodies additionally affect disease progression. The introduction of engineered mAbs for anticancer immunotherapies has substantially improved progression-free and overall survival of cancer patients, but little efforts have been made to exploit other antibody isotypes than IgG.

RECENT FINDINGS: In order to improve these therapies, 'next-generation antibodies' were engineered to enhance a specific feature of classical antibodies and form a group of highly effective and precise therapy compounds. Advanced antibody approaches include among others antibody-drug conjugates, glyco-engineered and Fc-engineered antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies and alternative (non-IgG) immunoglobulin classes, especially IgE.

SUMMARY: The current review describes solutions for the needs of next-generation antibody therapies through different approaches. Careful selection of the best-suited engineering methodology is a key factor in developing personalized, more specific and more efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential next-generation anticancer immunotherapy.

Original languageEnglish
Pages (from-to)282-289
Number of pages8
JournalCurrent Opinion in Allergy and Clinical Immunology
Issue number3
Publication statusPublished - 01 Jun 2020


  • Antibodies, Bispecific/therapeutic use
  • Antibodies, Monoclonal/therapeutic use
  • Antineoplastic Agents, Immunological/therapeutic use
  • Drug Resistance, Neoplasm/genetics
  • Humans
  • Immunoconjugates/therapeutic use
  • Immunoglobulin E/therapeutic use
  • Immunoglobulin Fc Fragments/therapeutic use
  • Medical Oncology/methods
  • Neoplasms/drug therapy
  • Precision Medicine/methods
  • Progression-Free Survival
  • Protein Engineering
  • Radioimmunotherapy/methods
  • Tumor Escape/genetics
  • tumor-associated antigens
  • allergooncology
  • IgE
  • immunotherapy of cancer
  • antibody optimization approaches

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Precision medicine in clinical oncology: the journey from IgG antibody to IgE'. Together they form a unique fingerprint.

Cite this